Compare KeyCorp (KEY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Spyre Therapeutics Inc. Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: KeyCorp is far larger — about 2.9× Spyre Therapeutics Inc. Common Stock's market cap, and KeyCorp pays a 4.12% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KEY | SYRE | |
|---|---|---|
Market Cap | $21.25B | $7.35B |
Volume | 17,676,934 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $23.99 | $108.92 |
52-Week Low | $16.78 | $22.18 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $6.35B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.91, down 0.9% on the day, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Analyst consensus remains strongly bullish with a $25.00 price target, representing 25% upside potential. Recent corporate developments include leadership appointments and a maintained dividend payout.
KEY presents a compelling value opportunity with attractive valuation metrics (P/E 11.64, P/B 1.23) and improving profitability (26.72% net margin). However, technical indicators signal near-term weakness, and the stock faces headwinds from interest rate sensitivity and competitive pressure on dividends. The disconnect between strong fundamentals and bearish technicals creates potential for recovery if earnings momentum continues.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
